FastWave's Laser IVL System Threatens the Cardiovascular Status Quo

MINNEAPOLIS, MN – September 29, 2026 — In the modern landscape of medical technology, true value creation rarely stems from iterative tweaks. It emerges from structural shifts—technologies that look at an established, multi-billion-dollar monopoly and identify the friction points the incumbent left behind. For the past several years, the intravascular lithotripsy (IVL) market has been defined by a single dominant player, relying on electrical spark-gap technology to fracture arterial calcium. But a new dataset suggests that the era of the IVL monopoly may be drawing to a close.

FastWave Medical, a Minneapolis-based medtech startup, today announced highly anticipated positive interim results from the first-in-human (FIH) feasibility study of its Sola™ laser IVL (L-IVL) system. Designed to treat complex calcified coronary artery disease, the Sola platform utilizes a novel laser-driven acoustic shockwave mechanism that promises to be faster, more deliverable, and highly controlled.

The 30-patient study, conducted across two clinical sites, delivered a 96.4% procedural success rate among the 28 patients in whom stent delivery was attempted. Crucially for an early-stage cardiovascular device, there were zero serious adverse events related to the study device reported through the 30-day follow-up period. As the industry parses these numbers, it is becoming clear that FastWave is not merely participating in the IVL space; it is actively engineering a disruption.

Cracking the Code on Severe Calcium

To understand the significance of FastWave's data, one must understand the mechanical nightmare of calcified coronary artery disease. When plaque in the arteries hardens into bone-like calcium, traditional balloon angioplasty often fails. If a physician cannot crack the calcium, a subsequently placed stent will not fully expand, leaving the patient vulnerable to restenosis, thrombosis, and a cascade of major adverse cardiovascular events.

The Sola system's interim results demonstrated profound efficacy in vessel preparation. Site-reported intravascular imaging confirmed calcium fracture in all 30 treated lesions—a 100% success rate on the fundamental mechanical objective of lithotripsy.

Following the L-IVL treatment and prior to stent implantation, the mean minimum lumen area increased by 49%. This acute luminal gain is the critical metric for interventional cardiologists; it represents the physical space reclaimed from the disease, allowing for optimal stent expansion. Furthermore, the mean diameter stenosis plummeted from a severe 79.1% at baseline to just 12.1% following the completion of the procedure.

These results were achieved in highly complex anatomy, with treated lesions averaging 32.6 mm in length. While stent delivery was attempted in 28 of the 30 patients—a standard variance in first-in-human trials where extreme anatomical complexities or alternative treatment decisions occasionally preclude immediate stenting—the procedural success rate of 96.4% remains a powerful validator of the system's core capability.

"What stood out to me with the Sola L-IVL system was its deliverability, along with the combination of control and speed," said Arthur Lee, MD, FACC, FSCAI, Director of Vascular Services at The Cardiac & Vascular Institute (TCAVI), who performed cases in the study. "The ability to translate the optical emitter provides a differentiated way to direct lithotripsy along the lesion, while the 5-Hz pulse rate enables rapid energy delivery. Seeing calcium fracture in every treated lesion and meaningful luminal gain before stenting is very encouraging."

A Laser-Focused Threat to the IVL Monopoly

The commercial implications of FastWave's clinical success are impossible to ignore. The current IVL market is heavily dominated by Johnson & Johnson MedTech, following its massive acquisition of Shockwave Medical. Shockwave pioneered the space using spark-gap technology, which creates acoustic pressure waves via electrical discharge. While revolutionary at its inception, first-generation IVL has known limitations, particularly regarding the size and flexibility of the catheter, heat dissipation, balloon fatigue, and procedural speed.

FastWave's Sola system attacks these friction points directly by replacing the electrical spark with a laser. The low-profile catheter architecture houses a single actuating optical emitter. Because it uses light rather than electricity to generate the acoustic pressure wave, the system bypasses the thermal and physical constraints of spark-gap emitters.

Perhaps the most striking differentiator is speed. The Sola system pulses energy up to five times faster than conventional IVL, operating at a 5-Hz pulse rate. Additionally, the physician-controlled translating emitter allows the operator to deliver circumferential acoustic pressure along the entire length of the target lesion without repeatedly repositioning the catheter. For interventional cardiologists operating on long, 32-millimeter lesions, this translates to fewer procedural steps, shorter case times, and reduced radiation exposure.

"These interim results are encouraging, particularly the consistency of calcium fracture and luminal gain we observed before stent implantation," said Scott Nelson, CEO of FastWave Medical. "Combined with the procedural outcomes from this first-in-human experience, the findings give us confidence as we continue advancing Sola toward a future coronary IDE trial."

The Dual-Front Regulatory Strategy

Developing a novel cardiovascular device requires immense capital and strategic foresight. FastWave, founded in 2021 by industry veterans, has secured over $50 million in venture funding to ensure it has the runway to navigate the FDA's rigorous regulatory crucible. But rather than relying on a single asset, the company is executing a highly ambitious dual-platform strategy.

While Sola targets the coronary arteries, FastWave is simultaneously advancing its Artero™ electric IVL (E-IVL) system for peripheral artery disease. The company recently received FDA Investigational Device Exemption (IDE) approval to begin the U.S. pivotal trial for Artero, known as the SPARC study, which is expected to enroll up to 125 patients across 30 sites.

"Between our recent peripheral IDE approval and these interim coronary results, both of FastWave's IVL platforms have achieved important clinical and regulatory milestones," said Tristan Tieso, COO of FastWave Medical. "We're focused on building on that momentum as we advance our peripheral pivotal program and prepare Sola for its next stage of clinical development."

The path forward for Sola will require mirroring the scale of historical IVL approvals. FastWave intends to seek IDE approval for a coronary pivotal trial in 2027. If historical precedents—such as Shockwave's Disrupt CAD III trial, which enrolled over 400 patients—are any indication, FastWave will need to execute a massive, multi-center study to secure Premarket Approval (PMA) from the FDA.

To ensure the integrity of its data as it approaches this next phase, FastWave's current single-arm feasibility results are undergoing independent core laboratory assessment. Specialized core labs will provide unbiased adjudication of the angiographic and intravascular imaging data, a necessary step to validate the investigator-reported 100% calcium fracture rate and 49% luminal gain before the FDA review.

The Mechanics of a MedTech Contender

Resilience in the medical device sector is defined by a company's ability to look at a solved problem and ask if it can be solved better. Intravascular lithotripsy is no longer a speculative science; it is the standard of care for severe arterial calcium. The question now is which technology will define the next decade of the procedure.

With its Fierce 15 designation and recognition as MD+DI's 2025 Medtech Company of the Year, FastWave is rapidly shedding its status as a stealth startup and emerging as a formidable challenger. By leveraging laser technology to improve catheter deliverability, exponentially increase pulse speed, and simplify usability, the company is systematically dismantling the technical compromises inherent in first-generation devices.

The 30-patient feasibility data for the Sola system is an interim snapshot, but it is a remarkably clear one. It reveals a technology that performs exactly as engineered under the high-stakes conditions of the catheterization lab. As FastWave scales its clinical operations and prepares for pivotal IDE trials on both the coronary and peripheral fronts, the broader medtech industry will be watching closely. The race to redefine intravascular lithotripsy has officially begun, and the incumbent monopoly is no longer running unopposed.